South Africa Neurology Clinical Trials Market Report 2022 to 2030

South Africa Neurology Clinical Trials Market Analysis

$ 3999

The South Africa Neurology Clinical Trials market is projected to grow from $34 Mn in 2022 to $57.2 Mn by 2030, registering a CAGR of 6.73% during the forecast period of 2022 - 2030. The market will be driven by the availability of a diverse population, a large number of well-trained healthcare professionals and modern medical healthcare facilities. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Eli Lilly and Company & Biovac.

ID: IN10ZACT005 CATEGORY: Clinical Trials GEOGRAPHY: South Africa AUTHOR: Vidhi Upadhyay

Buy Now

South Africa Neurology Clinical Trials Market Executive Summary

The South Africa Neurology Clinical Trials market is projected to grow from $34 Mn in 2022 to $57.2 Mn by 2030, registering a CAGR of 6.73% during the forecast period of 2022 - 2030. South Africa ranks second, accounting for 19.9% of studies, followed by Uganda and Kenya, for clinical trials undertaken in Africa. Neurological disorders caused by neuro infections are very common in Sub-Saharan Africa (SSA), posing a significant impairment and economic burden on individuals and society. Epilepsy, dementia, motor neuron diseases, headache problems, sleep disorders, and peripheral neuropathy were among them. According to the most recent WHO statistics, Alzheimer's and Dementia fatalities in South Africa reached 4,676 in 2020, accounting for 1.03% of all fatalities.

Clinical trials are an important component of medical research since they are used to assess the safety and effectiveness of novel medications, medical equipment, or therapies. Clinical trials are carried out to ensure that novel therapy or medicines are safe, effective, and suitable for use in the treatment of patients. Neurology clinical trials especially concentrate on therapies for neurological illnesses, including Alzheimer's disease, multiple sclerosis, Parkinson's disease, stroke and others. South Africa has a well-developed healthcare system and has been active in clinical studies for many years. The country's population is diversified, making it an appealing site for clinical studies that need a broad patient group. Moreover, South Africa is a popular location for international clinical trials due to its high number of well-trained healthcare personnel and advanced medical facilities.

The South African Health Products Regulatory Authority (SAHPRA) is the regulatory body in charge of pharmaceuticals, clinical trials, medical devices, and radiation safety in South Africa. As stated in the Medicines and Related Substances Act (MRSA), Medicines and Related Substances Act, General Regulations (GRMRSA), and ZAF-10, SAHPRA is responsible for clinical trial monitoring, approval, and examinations in South Africa. In line with the rules of the GRMRSA, the agency gives authorisation for clinical studies to be undertaken in South Africa.

South Africa Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

Many variables influence the South African neurology clinical trials market. The prevalence of neurological illnesses such as Alzheimer's disease, multiple sclerosis, and Parkinson's disease is increasing in South Africa. As a consequence, there is a growing need for innovative and effective therapies for these disorders, resulting in an increase in demand for neurology clinical trials in the nation. South Africa's healthcare system is well-developed, with sophisticated medical facilities, a huge pool of well-trained healthcare personnel, and a diversified patient population. These qualities make South Africa an appealing destination for clinical trials, especially those requiring a varied patient group. Moreover, the South African government has created regulatory authorities, such as The South African Health Products Regulatory Authority (SAHPRA), to oversee that clinical trials undertaken in the nation follow stringent ethical and safety criteria. This has produced a favourable climate for clinical trial sponsors, aiding in the expansion of the neurology clinical trials market.

Market Restraints

There are various factors influencing the neurology clinical trials industry in South Africa. To begin, the nation continues to confront enormous socioeconomic obstacles, such as poverty, inequality, and a high burden of infectious illnesses such as HIV/AIDS and TB. These limitations may make recruiting people for clinical trials challenging and may restrict the country's market potential for neurology clinical studies. Moreover, there are practical obstacles connected with conducting clinical trials in South Africa, such as infrastructure, transportation, and communication concerns. These obstacles may raise the expense and difficulty of conducting clinical trials in the nation, discouraging some sponsors from entering the market.

Competitive Landscape

Key Players

Pfizer Inc.
Novartis AG
Eli Lilly and Company
Roche Holding AG
Aspen Pharmacare (ZAF)
Adcock Ingram (ZAF)
Biovac (ZAF)
Centre for Clinical Studies (ZAF)
Morningside Clinical Trials (ZAF)
Synexus Clinical Research (ZAF)

Notable Deals

July 2021, Pfizer and BioNTech Establish a Partnership with Biovac to Produce and Distribute COVID-19 Vaccine Doses in Africa

December 2022, Lilly and EVA Pharma Establish Partnership to Provide Long-Term Access to Low-Cost Insulin in Africa

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.